Proton pump inhibitors (PPIs) are widely used medications to manage common digestive issues like heartburn, acid reflux, and gastroesophageal reflux disease (GERD).
Popular brands, such as Prilosec, Nexium, and Prevacid, are taken by about 10% of adults in the United States to relieve symptoms that can interfere with daily life.
While these drugs are helpful for many people, recent research suggests that PPIs may come with hidden risks, especially to kidney health.
A research team from the University of California San Diego recently conducted a study to explore these potential risks.
Using the FDA Adverse Event Reporting System (FAERS) database, which contains millions of reports from patients who experienced side effects with medications, they focused on data related to kidney health among people using PPIs.
From this massive database, the researchers narrowed down their study to approximately 43,000 patients who took PPIs exclusively, without combining them with other medications.
To provide a comparison, the team also looked at a control group of about 8,000 patients who only took a different type of heartburn medication known as histamine-2 receptor antagonists, or H2 blockers.
Examples of H2 blockers include Zantac and Pepcid, which work differently than PPIs to reduce stomach acid.
The findings revealed a concerning trend: patients who took PPIs alone reported kidney-related side effects at a rate of 5.6%, significantly higher than the 0.7% rate in patients who took only H2 blockers.
Specifically, people on PPIs alone were found to be 28.4 times more likely to report chronic kidney disease compared to the control group.
They also faced a higher risk of serious kidney issues such as acute kidney injury (4.2 times more likely), end-stage renal disease (35.5 times more likely), and unspecified kidney impairment (8 times more likely).
Electrolyte imbalances, which affect fluid balance and overall kidney function, were also noted, although these varied depending on the specific PPI taken. In contrast, the risk of kidney problems was more consistent across all five PPIs studied.
These findings suggest that while PPIs are effective for managing acid-related symptoms, they may increase the risk of kidney disease.
According to the World Health Organization, PPIs are essential for many people, offering relief from symptoms that can be both painful and disruptive.
However, the researchers hope their study will encourage healthcare providers to share this information with patients, especially those who are already at a higher risk of kidney disease.
Proper monitoring and education could help patients make informed decisions about their treatment options.
It’s also worth noting that this is not the first time PPIs have raised concerns. A previous study from 2017 by the UC San Diego School of Medicine found evidence in mice and humans that PPIs might contribute to chronic liver disease. This suggests that PPIs may affect not only kidney health but also other organs over time.
For those concerned about kidney health, it’s important to have regular check-ups and be aware of potential risks with medications. Alternative treatments, such as H2 blockers, may be suitable for some people, especially if kidney health is already a concern.
Further studies are likely to explore this topic, but for now, the research offers a reminder of the importance of carefully weighing the benefits and risks of medications.
If you care about medicine, please read studies that vitamin D could help lower the risk of autoimmune diseases, and drug for inflammation may stop spread of cancer.
For more information about medicine, please see recent studies about which drug can harm your liver most, and results showing this drug can give your immune system a double boost against cancer.
Copyright © 2024 Knowridge Science Report. All rights reserved.
